Advanced Biomed
Financial-market AI systems with biomedical R&D pending sale.
Something off on this page? Send us feedback.
Profile
Develops FinLLM and FinTruth for regulated financial markets after shifting from biomedical R&D; the AI operation's pricing and commercial model have not been disclosed, and its Taiwan R&D subsidiary is pending sale.
Runs FinLLM, a financial-domain language model, and FinTruth, a verification system designed for precision, explainability, and compliance in regulated financial markets. The systems came with the acquisition of Hong Kong-based Acellent, which made AI the primary focus for a Nevada parent with its principal executive office in Tainan City, Taiwan.
Repeated corporate restructuring, including the AI acquisition and subsidiary sales, has been the clearest observed operating pattern. Retains, pending sale, the Taiwan subsidiary that conducts biomedical R&D, including the A+PerfusC perfusion cell-culture incubator and a legacy portfolio for circulating-tumor-cell workflows. Customer, pricing, and revenue data for the AI operation have not been disclosed, while biomedical products depend on applicable regulatory approvals before sale.
Company facts
Key statistics
Year to date +61.4% · Average volume (30d) 3.6M
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| May 15, 2026Q3 FY26 | — | −$0.38 | — | — | — | — | +3.86% |
| Feb 13, 2026Q2 FY26 | — | $0.32 | — | — | — | — | −0.63% |
| Nov 19, 2025Q1 FY26 | — | −$0.02 | — | — | — | — | −8.71% |
| Oct 8, 2025Q1 FY26 | — | −$0.03 | — | — | — | — | +1.81% |
Financial highlights
| 12 quarters | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | — | $0 | — | $0 | — | −$294 | |
| Operating income | — | −$762.7K | −$39.3K | −$523.9K | −$12.8K | −$519.8K | |
| Net income | −$28.1K | −$1.4M | −$22.7K | −$386.9K | $220.9K | −$488.9K | |
| Diluted EPS | −$0.03 | −$0.04 | −$0.02 | −$0.01 | $0.20 | −$0.38 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Mar 31, 2026Cash & short-term investments $2.6M · Total debt $712.5K · Total assets $10.6M · Shareholders' equity $9.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 1.38M · Float 561.3K · 40.6% free float
Insiders — no current Form 4 position.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Pau Hung To | 176.2K | 12.75% | 13G | Aug 20, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- IBM
Enterprise AI governance overlaps in verification and compliance.
- Moody's
Financial-market GenAI research competes in analyst workflows.
- Thomson Reuters
Audit and compliance AI overlaps in regulated finance workflows.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Advanced Biomed | $9.76 | +0.10% | $13.4M | — | — | — | — |
| IBM | $235.80 | +0.10% | $221.96B | 20.8 | 18.4 | 3.2 | +1.1% |
| Moody's | $519.27 | +0.84% | $89.19B | 32.7 | 28.9 | 10.9 | +15.1% |
| Thomson Reuters | $106.23 | −0.03% | $46.37B | 28.4 | 22.2 | 5.9 | +7.0% |
| Median | 28.4 | 22.2 | 5.9 | +7.0% |